GRTS.Q Stock Overview
A clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Gritstone bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.013 |
| 52 Week High | US$3.17 |
| 52 Week Low | US$0.0029 |
| Beta | 0.64 |
| 1 Month Change | -59.68% |
| 3 Month Change | -97.93% |
| 1 Year Change | -99.39% |
| 3 Year Change | -99.90% |
| 5 Year Change | -99.85% |
| Change since IPO | -99.91% |
Recent News & Updates
Recent updates
We Think Some Shareholders May Hesitate To Increase Gritstone bio, Inc.'s (NASDAQ:GRTS) CEO Compensation
Jun 11
Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering
Apr 07Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%
Aug 14Gritstone bio: Early Data For SLATE Candidate Sets Up 2023 Catalyst
Sep 26Gritstone reaches six-month high on publication of data for cancer vaccine
Aug 16Gritstone bio announces $80M credit facility
Jul 21Is Gritstone bio (NASDAQ:GRTS) In A Good Position To Invest In Growth?
Jul 07Gritstone bio: Potential To Advance Colorectal Cancer Treatment
Jul 05Gritstone bio: Investing In A Premium mRNA Technology At A Discounted Valuation
Jun 14Some Analysts Just Cut Their Gritstone bio, Inc. (NASDAQ:GRTS) Estimates
Mar 17We're Not Very Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Rate
Mar 05Gritstone: Why The Stock Fell On Positive Data
Jan 18Shareholder Returns
| GRTS.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -26.0% | 2.1% | 2.8% |
| 1Y | -99.4% | -3.8% | 24.5% |
Return vs Industry: GRTS.Q underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: GRTS.Q underperformed the US Market which returned 24.8% over the past year.
Price Volatility
| GRTS.Q volatility | |
|---|---|
| GRTS.Q Average Weekly Movement | 49.5% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GRTS.Q's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GRTS.Q's weekly volatility has increased from 28% to 49% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 231 | Andrew Allen | gritstonebio.com |
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors.
Gritstone bio, Inc. Fundamentals Summary
| GRTS.Q fundamental statistics | |
|---|---|
| Market cap | US$1.48m |
| Earnings (TTM) | -US$133.03m |
| Revenue (TTM) | US$14.61m |
0.1x
P/S Ratio0.0x
P/E RatioIs GRTS.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRTS.Q income statement (TTM) | |
|---|---|
| Revenue | US$14.61m |
| Cost of Revenue | US$119.55m |
| Gross Profit | -US$104.94m |
| Other Expenses | US$28.09m |
| Earnings | -US$133.03m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.13 |
| Gross Margin | -718.30% |
| Net Profit Margin | -910.56% |
| Debt/Equity Ratio | 182.5% |
How did GRTS.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 06:33 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Gritstone bio, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Corinne Johnson | Goldman Sachs |
| Douglas Buchanan | JMP Securities |